BioClinica
announced it has created strategic partnerships with two privately held clinical research organizations (CROs),
Axio Research Corporation
and
Beardsworth Consulting Group, Inc.
Both alliances strengthen the
BioClinica Certified Partner Program
and provide customers with additional support in complex therapeutic areas of study and data monitoring and management.
Mark Weinstein, CEO of BioClinica, Inc. "Both Axio Research and Beardsworth match the quality and industry leadership of all partners recognized by the BioClinica Certified Partner Program, and we are pleased to offer our customers this expanded support. Our certified partners now represent a collective experience of over 1000 trials in more than 6000 sites across 52 countries."
Since 1979, Axio Research has provided data management, statistical and medical writing services for industry, government, and academic sponsors in the clinical research field. Based in Seattle, Washington, the company also provides clinical trial design and clinical events committee support services, and serves as the independent statistical center for Data Monitoring Committees.
Based in Flemington, New Jersey, Beardsworth is a specialty CRO in Oncology, delivering a broad range of clinical research services to pharmaceutical and biotechnology companies. Since 1986, the company has focused on complicated trials in complex therapeutic areas, utilizing an internal paper-based data management system.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Gilead Shares Final Data from Phase III MYR301 Trial of Bulevirtide in Chronic Hepatitis Delta Virus
May 7th 2025Long-term results from the study show 90% of patients with chronic HDV who achieved undetectable HDV RNA at 96 weeks of treatment remained undetectable for nearly 2 years post-treatment.